Novavax logo

Novavax

Stock
Stock
Ticker: NVAX
NVAX

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Novavax is $1.48B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Novavax's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.523. EPS indicates the company's profitability on a per-share basis.
Currently, 7 analysts cover Novavax's stock, with a consensus target price of $14.71. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Novavax reported a revenue of $413.80M.
Novavax's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$101.43M. EBITDA measures the company's overall financial performance.
Novavax has a free cash flow of -$42.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Novavax employs approximately 749 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Novavax is 156.72M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$1.48B
EPS (TTM) 
-$1.523
Free Float 
156.72M
Revenue (TTM) 
$413.80M
EBITDA (TTM) 
-$101.43M
Free Cashflow (TTM) 
-$42.85M

Pricing

1D span
$8.906$9.345
52W span
$6.205$11.96

Analyst Ratings

The price target is $14.71 and the stock is covered by 7 analysts.

Buy

4

Hold

1

Sell

2

Information

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Employees
749
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
NVAX

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation